ImportantAMGN
Explain this story: AMGN Maintains Rating by Scotiabank -- Price Target Raised to $5
Explain like I'm 7
A expert raised the price he thinks Amgen's stock could reach, from $450 to $500. But another group said the stock's current price seems too high for what the company is worth.
Analyst action · Price target raised from $450 to $500GuruFocusSector and industry: HealthcareBiotechnologyTell me moreShow less
Explain like I'm 7
A expert raised the price he thinks Amgen's stock could reach, from $450 to $500. But another group said the stock's current price seems too high for what the company is worth.
What happenedFrom the article
- Scotiabank Louise Chen maintained a ' Outperform' rating on Amgen.
- The was raised from $450.00 to $500.00.
- GuruFocus assessed AMGN's price as 13.4% above its estimated value, with the stock trading at $416.98.
- Amgen holds a GF Score of 87/100, described as driven by excellent profitability and growth, but with weaker momentum.